{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T02:25:58Z","timestamp":1780539958733,"version":"3.54.1"},"reference-count":24,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2024,9,9]],"date-time":"2024-09-09T00:00:00Z","timestamp":1725840000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["headachejournal.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Headache"],"published-print":{"date-parts":[[2025,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To assess changes in real\u2010world use of acute and preventive medications for migraine over a 12\u2010month follow\u2010up period in the United States following initiation of the anti\u2010calcitonin gene\u2010related peptide (CGRP) pathway monoclonal antibody (mAb) erenumab.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Early assessments of real\u2010world use of acute and preventive medications for migraine after initiation of erenumab have been limited to 6\u2009months of follow\u2010up.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective cohort study used data from the IQVIA open\u2010source longitudinal prescription (LRx) and medical (Dx) claims databases. Adult patients with an initial claim (index date) for erenumab between May 2018 and April 2020 were identified.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Among 201,176 patients who met inclusion criteria, the mean (standard deviation [SD]) age was 47.5\u2009(13.8)\u2009years and 85.6% (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009172,153) were female. Most patients used one or more acute (88.4%;\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009177,795) and one or more traditional preventive (86.1%;\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009173,225) medications during the 12\u2010month pre\u2010index period. Adherence to erenumab (proportion of days covered [PDC] \u22650.80) was 40.2% (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200980,927) with an overall mean (SD) PDC of 0.60\u2009(0.34). Among all patients, 70.0% (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009140,809) discontinued erenumab. After accounting for 24.7% (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200949,720) of patients who restarted erenumab, discontinuation without reinitiation was observed in 45.3% (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200991,089) of total patients. Switching to a different anti\u2010CGRP pathway mAb was observed in 13.1% (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200926,446) of total patients. Among 177,795 patients with pre\u2010index use of one or more acute migraine medication class, 86.5% (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009153,788) had post\u2010index use of the same class, and 56.7% (87,134\/153,788) of them discontinued one or more class of acute medication in the 12\u2010month follow\u2010up period. Similarly, among 173,225 patients with pre\u2010index use of one or more traditional migraine preventive medication class, 67.7% (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009117,274) had post\u2010index use of the same class, and 46.7% (54,790\/117,274) of them discontinued one or more class of traditional preventive medication in the 12\u2010month follow\u2010up period.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In this long\u2010term study, we observed the discontinuation of both acute and preventive medications for migraine post\u2010erenumab initiation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/head.14820","type":"journal-article","created":{"date-parts":[[2024,9,9]],"date-time":"2024-09-09T06:03:05Z","timestamp":1725861785000},"page":"68-79","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Changes in use of acute and preventive medications for migraine after erenumab initiation over 12\u2009months: A United States retrospective cohort study"],"prefix":"10.1111","volume":"65","author":[{"given":"Jasjit K.","family":"Multani","sequence":"first","affiliation":[{"name":"IQVIA  Falls Church Virginia USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Urman","sequence":"additional","affiliation":[{"name":"Amgen Inc.  Thousand Oaks California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew S.","family":"Park","sequence":"additional","affiliation":[{"name":"Amgen Inc.  Thousand Oaks California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karminder","family":"Gill","sequence":"additional","affiliation":[{"name":"Amgen Inc.  Thousand Oaks California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiston","family":"Vuvu","sequence":"additional","affiliation":[{"name":"Amgen Inc.  Thousand Oaks California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kainan","family":"Sun","sequence":"additional","affiliation":[{"name":"IQVIA  Falls Church Virginia USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leah B.","family":"Patel","sequence":"additional","affiliation":[{"name":"Amgen Inc.  Thousand Oaks California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen M.","family":"Stockl","sequence":"additional","affiliation":[{"name":"IQVIA  Falls Church Virginia USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Hawkins","sequence":"additional","affiliation":[{"name":"IQVIA  Falls Church Virginia USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Rhyne","sequence":"additional","affiliation":[{"name":"Diamond Headache Clinic  Chicago Illinois USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark E.","family":"Bensink","sequence":"additional","affiliation":[{"name":"Benofit Consulting  Brisbane Queensland Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,9,9]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30925-9"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524-4733.2008.00404.x"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.14024"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000252808.97649.21"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102410381145"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102411398400"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.13456"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-159-8-201310150-02011"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11916-015-0521-0"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2014.20.1.22"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102414547138"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102416678382"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2020.20100"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-019-01069-1"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40120-021-00245-4"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.14068"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40122-021-00319-z"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-020-01143-0"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.14218"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-021-01292-w"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2021.21060"},{"key":"e_1_2_11_23_1","article-title":"Changes in acute migraine\u2010specific medications after initiating erenumab: results from a real\u2010world retrospective cohort study in the United States","volume":"94","author":"Hines D","year":"2020","journal-title":"Eur J Neurol"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-021-01677-y"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.2147\/PPA.S346660"}],"container-title":["Headache: The Journal of Head and Face Pain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/headachejournal.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/head.14820","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T11:41:39Z","timestamp":1762083699000},"score":1,"resource":{"primary":{"URL":"https:\/\/headachejournal.onlinelibrary.wiley.com\/doi\/10.1111\/head.14820"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,9]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["10.1111\/head.14820"],"URL":"https:\/\/doi.org\/10.1111\/head.14820","archive":["Portico"],"relation":{},"ISSN":["0017-8748","1526-4610"],"issn-type":[{"value":"0017-8748","type":"print"},{"value":"1526-4610","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,9]]},"assertion":[{"value":"2023-12-04","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-06-25","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-09-09","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}